Business Context and Reporting Period
This Form 8-K Current Report was filed by Medicus Pharma Ltd. (NASDAQ: MDCX) on September 12, 2025. The report discloses a material change in executive leadership effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of CFO: James Quinlan, Chief Financial Officer, is taking a medical leave of absence commencing September 12, 2025.
- Appointment of Acting CFO: Carolyn Bonner, currently the President of the Company (since September 2023), has been appointed as Acting Chief Financial Officer.
- Compensation: Ms. Bonner will not receive additional compensation for her service as Acting CFO and has not entered into a new agreement for this role.
Management Commentary and Risks
The filing provides background on Ms. Bonner's qualifications, noting her previous roles as President & CEO of Parkway Clinical Laboratories and Director of Corporate Development at Building Beyond BRIC Investment Fund. No specific risks, contingencies, or unusual items related to financial operations were disclosed in this text.
Investor Verification Checklist
- Verify the expected duration of James Quinlan's medical leave of absence.
- Confirm if a permanent CFO search has been initiated or if Ms. Bonner's role is intended to be long-term.
- Review upcoming quarterly reports for any impact on financial reporting timelines due to the leadership transition.